Experimental models used in evaluating anti-tuberculosis vaccines: the latest advances in the field
Introduction: Tuberculosis is an infectious disease which is caused by bacilli from the M. tuberculosis complex. The Mycobacterium bovis Bacillus Calmette-Guérin vaccine is currently available as a prophylactic tool for preventing the disease; it has been shown to be efficient in preventing dissemin...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2019-04-01
|
| Series: | Expert Review of Vaccines |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/14760584.2019.1583558 |
| _version_ | 1797680332442435584 |
|---|---|
| author | Alejandra Mantilla Galindo Marisol Ocampo Manuel Alfonso Patarroyo |
| author_facet | Alejandra Mantilla Galindo Marisol Ocampo Manuel Alfonso Patarroyo |
| author_sort | Alejandra Mantilla Galindo |
| collection | DOAJ |
| description | Introduction: Tuberculosis is an infectious disease which is caused by bacilli from the M. tuberculosis complex. The Mycobacterium bovis Bacillus Calmette-Guérin vaccine is currently available as a prophylactic tool for preventing the disease; it has been shown to be efficient in preventing disseminated forms of tuberculosis during early ages; however, its efficiency is limited in areas where individuals have had prior exposure to environmental mycobacteria, and its efficacy decreases with a host’s age. Areas covered: Following a comprehensive search of the available literature, this review describes some of the most frequently used animal models, the most frequently used methods for evaluating efficacy in animal models and some in vitro strategies as alternatives for evaluating vaccines. Expert opinion: Identifying the animal models used up to now for evaluating vaccines during their development stages, their characteristics and limitations, as well as knowledge regarding strategies for evaluating promising vaccine candidate efficacy, will ensure more efficient, reliable and reproducible pre-clinical trials. Although much of the knowledge accrued to date concerning vaccine effectiveness against tuberculosis has been based on animal models, it is clear that large questions still need to be resolved and that extrapolation of such efficacy to humans has yet to be achieved. |
| first_indexed | 2024-03-11T23:28:27Z |
| format | Article |
| id | doaj.art-04baba11da184ea2a74d9af64e050548 |
| institution | Directory Open Access Journal |
| issn | 1476-0584 1744-8395 |
| language | English |
| last_indexed | 2024-03-11T23:28:27Z |
| publishDate | 2019-04-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Expert Review of Vaccines |
| spelling | doaj.art-04baba11da184ea2a74d9af64e0505482023-09-20T10:18:04ZengTaylor & Francis GroupExpert Review of Vaccines1476-05841744-83952019-04-0118436537710.1080/14760584.2019.15835581583558Experimental models used in evaluating anti-tuberculosis vaccines: the latest advances in the fieldAlejandra Mantilla Galindo0Marisol Ocampo1Manuel Alfonso Patarroyo2Universidad del RosarioUniversidad del RosarioUniversidad del RosarioIntroduction: Tuberculosis is an infectious disease which is caused by bacilli from the M. tuberculosis complex. The Mycobacterium bovis Bacillus Calmette-Guérin vaccine is currently available as a prophylactic tool for preventing the disease; it has been shown to be efficient in preventing disseminated forms of tuberculosis during early ages; however, its efficiency is limited in areas where individuals have had prior exposure to environmental mycobacteria, and its efficacy decreases with a host’s age. Areas covered: Following a comprehensive search of the available literature, this review describes some of the most frequently used animal models, the most frequently used methods for evaluating efficacy in animal models and some in vitro strategies as alternatives for evaluating vaccines. Expert opinion: Identifying the animal models used up to now for evaluating vaccines during their development stages, their characteristics and limitations, as well as knowledge regarding strategies for evaluating promising vaccine candidate efficacy, will ensure more efficient, reliable and reproducible pre-clinical trials. Although much of the knowledge accrued to date concerning vaccine effectiveness against tuberculosis has been based on animal models, it is clear that large questions still need to be resolved and that extrapolation of such efficacy to humans has yet to be achieved.http://dx.doi.org/10.1080/14760584.2019.1583558animal modelmycobacterium spptuberculosisvaccine |
| spellingShingle | Alejandra Mantilla Galindo Marisol Ocampo Manuel Alfonso Patarroyo Experimental models used in evaluating anti-tuberculosis vaccines: the latest advances in the field Expert Review of Vaccines animal model mycobacterium spp tuberculosis vaccine |
| title | Experimental models used in evaluating anti-tuberculosis vaccines: the latest advances in the field |
| title_full | Experimental models used in evaluating anti-tuberculosis vaccines: the latest advances in the field |
| title_fullStr | Experimental models used in evaluating anti-tuberculosis vaccines: the latest advances in the field |
| title_full_unstemmed | Experimental models used in evaluating anti-tuberculosis vaccines: the latest advances in the field |
| title_short | Experimental models used in evaluating anti-tuberculosis vaccines: the latest advances in the field |
| title_sort | experimental models used in evaluating anti tuberculosis vaccines the latest advances in the field |
| topic | animal model mycobacterium spp tuberculosis vaccine |
| url | http://dx.doi.org/10.1080/14760584.2019.1583558 |
| work_keys_str_mv | AT alejandramantillagalindo experimentalmodelsusedinevaluatingantituberculosisvaccinesthelatestadvancesinthefield AT marisolocampo experimentalmodelsusedinevaluatingantituberculosisvaccinesthelatestadvancesinthefield AT manuelalfonsopatarroyo experimentalmodelsusedinevaluatingantituberculosisvaccinesthelatestadvancesinthefield |